Yokobori K, Miyauchi Y, Williams JG, Negishi M (2020) Phosphorylation of vaccinia-related kinase 1 at threonine 386 transduces glucose stress signal in human liver cells. Biosci Rep 40 32266931

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S63-p - Jun (human) ▲

Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene Orthologous residues Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  Huh7 (hepatic) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE VRK1 (human) phospho-antibody, siRNA inhibition of enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes low_glucose increase siRNA low_glucose inhibit treatment-induced increase VRK1 siRNA low_glucose plakophilin 2 (human) augment treatment-induced increase PKP2 siRNA inhibits

T18-p - p53 (human) ▲

Modsite: EPPLsQEtFsDLWkL SwissProt Entrez-Gene Orthologous residues p53 (human): T18‑p, p53 iso2 (human): T18‑p, p53 iso4 (human): ‑, p53 (mouse): T21‑p, p53 iso2 (mouse): T21‑p, p53 (rat): T18‑p, p53 (rabbit): T18‑p, p53 (green monkey): T18‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  Huh7 (hepatic) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE VRK1 (human) phospho-antibody, siRNA inhibition of enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes low_glucose increase siRNA low_glucose inhibit treatment-induced increase VRK1 siRNA low_glucose plakophilin 2 (human) no effect upon treatment-induced increase high_glucose VRK1 (human) increase VRK1 siRNA

S376-p - VRK1 (human) ▲

Modsite: GVEDTEWsNtQtEEA SwissProt Entrez-Gene Orthologous residues VRK1 (human): S376‑p, VRK1 (mouse): S376‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  Huh7 (hepatic) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE VRK1 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes low_glucose no change compared to control UV increase

T386-p - VRK1 (human) ▲

Modsite: QtEEAIQtRSRTRKR SwissProt Entrez-Gene Orthologous residues VRK1 (human): T386‑p, VRK1 (mouse): T386‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  liver cancer, hepatocellular carcinoma Relevant cell lines - cell types - tissues:  Huh7 (hepatic) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE VRK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE VRK1 (human) transfection of wild-type enzyme, transfection of inactive enzyme Autophosphorylation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes low_glucose increase UV no change compared to control low_glucose plakophilin 2 (human) augment treatment-induced increase PKP2 siRNA inhibits Downstream Regulation Effect of modification (function):  phosphorylation Comments:  induces phosphorylation of c-Jun and p53